Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of Gefitinib
Page 1 Phase II Study of Erlotinib in Advanced Non–Small-Cell Lung Cancer After Failure of …

PURPOSE: The use of erlotinib after gefitinib failure in patients with non-small cell lung
cancer (NSCLC) is not clearly clarified in clinical practice. We sought to compile the …

Background: Both gefitinib and erlotinib are reversible epidermal growth factor receptor
tyrosine kinase inhibitors, but they have somewhat different pharmacological properties. We …

BACKGROUND: Gefitinib and erlotinib are commonly used for salvage therapy in patients
with nonsmall cell lung cancer (NSCLC) who have progressed on prior therapies. Although …

Purpose Chemotherapy is the mainstay treatment for advanced non-small cell lung cancer
(NSCLC). Gefitinib, an epidermal growth factor receptor—tyrosine kinase inhibitor (EGFR …

Background Gefitinib and erlotinib are two orally active epidermal growth factor receptor
tyrosine kinase inhibitors used in the treatment of advanced non-small cell lung cancer …

PURPOSE: Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this
randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib …

Previous studies have demonstrated that both gefitinib and erlotinib are markedly effective
for the treatment of non-small-cell lung cancer (NSCLC) with somatic activating mutations of …

Epidermal growth factor receptor (EGFR) has been extensively studied as a target in the
treatment of non-small cell lung cancer. Gefitinib (ZD 1839, Iressa) and erlotinib (OSI 774 …

Introduction We report the cases of three patients with advanced non-small cell lung cancer
responding to erlotinib after progression under gefitinib treatment. Methods Three never …